Editorially independent. Revenue never influences our rankings. · Updated weekly · Last reviewed May 20, 2026
Savings

GLP-1 Savings Strategies

Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.

Strategies for reducing the cost of GLP-1 therapy: insurance maximization, manufacturer programs, cash-pay compounded paths, and the tradeoffs of each.

If you have insurance

  1. Verify GLP-1 coverage with member services — get the formulary tier and PA criteria in writing.
  2. If covered for T2D: pursue Ozempic or Mounjaro through your insurance.
  3. If covered for weight: pursue Wegovy or Zepbound through PA.
  4. If covered for CV indication (BMI ≥27 + established CVD): Wegovy under March 2024 indication.
  5. If covered for OSA (BMI ≥30 + moderate-to-severe OSA): Zepbound under December 2024 indication.
  6. Use a manufacturer copay card if commercial: NovoCare Connect for Wegovy/Ozempic, Lilly Cares for Mounjaro/Zepbound.

If you don't have insurance coverage

  1. Manufacturer cash-pay programs: NovoCare Wegovy cash-pay $499/mo; Lilly Direct Zepbound vial from $349/mo.
  2. Cash-pay compounded: $145–$269/mo depending on agent and provider. Lowest annual cost for most patients without coverage.
  3. Manufacturer patient assistance: Income-qualified patients may access medication free or reduced-cost. Apply directly to manufacturer.
  4. Clinical trials: Active GLP-1 trials provide medication free during trial period. Check clinicaltrials.gov.

If your plan excludes weight-management drugs

  1. Check eligibility for non-weight indications you may qualify for (CV for Wegovy; OSA for Zepbound; T2D if newly diagnosed).
  2. Discuss with your employer's HR or benefits team — many large employers are reviewing weight-management coverage given the SELECT and SURMOUNT-OSA findings.
  3. Appeal denials with detailed medical-necessity documentation.
  4. Cash-pay compounded as an alternative path.

HSA and FSA

GLP-1 medications are HSA/FSA-eligible when prescribed for a medical indication. This includes both branded and compounded medications. Use pre-tax dollars where you can.

Tax considerations

Medical expenses exceeding 7.5% of AGI are tax-deductible. For high-cost GLP-1 paths (e.g., cash-pay branded Wegovy), this can be material.

Travel medication considerations

Some patients save by sourcing branded GLP-1 in countries with lower drug pricing. This carries import legality risks and supply chain risks. Not recommended; cash-pay compounded U.S. programs are generally a better path.

What we don't recommend

  • "Research chemical" semaglutide from non-pharmacy sources. Illegal, unregulated, and unsafe.
  • Programs that do not disclose pharmacy partner classification.
  • Sourcing branded GLP-1 from non-U.S. sources via grey-market channels.